期刊文献+

急性冠脉综合征患者血清OPG、sRANKL、OPG/sRANKL比值与冠状动脉粥样硬化斑块稳定程度的相关性 被引量:2

Relationship between levels/ratios of serum osteoprotegerin and sRANKL and stabilization of coronary artery atherosclerosis in patients with acute coronary syndrome
下载PDF
导出
摘要 目的:探讨急性冠脉综合征(ACS)患者血清骨保护素(osteoprotegerin,OPG)及其配体(souble-RANKL,sRANKL)和OPG/sRANKL比值与冠状动脉粥样硬化稳定程度的相关性。方法:纳入研究者分成3组:ACS患者(335例)、稳定型心绞痛(SAP)患者(120例)与正常对照组(120例)。其中ACS组又分为不稳定心绞痛(UAP组)134例,非ST段抬高型心肌梗死(NSTEMI组)80例以及ST段抬高型心肌梗死(STEMI)组121例3组。通过ELISA检测其血清OPG和sRANKL水平,并将二者血清水平及比值(OPG/sRANKL)与ACS冠状动脉粥样硬化斑块稳定程度进行比较分析。结果:ACS、SAP及对照组3组间血清OPG、sRANKL、OPG/sRANKL比值均有显著差异(均P<0.01)。ACS组内3组血清OPG、sRANKL、OPG/sRANKL比值也均有显著差异(均P<0.05),其中STEMI组与UAP组有显著差异(P<0.05),UAP组与NSTEMI组、NSTEMI与STEMI组间无显著差异。冠脉Gensini积分与血清OPG水平呈正相关(r=0.252,P<0.01),与OPG/sRANKL呈正相关(r=0.284,P<0.01),与血清sRANKL水平呈负相关(r=-0.235,P<0.05)。结论:血清OPG、sRANKL、OPG/sRANK比值与ACS病情及冠状动脉粥样硬化斑块稳定程度有关联。 AIM:To analyze the relationship between the osteoprotegerin(OPG) system and stabilization of coronary artery atherosclerosis in patients with acute coronary syndrome(ACS).METHODS: A total of 575 consecutive patients were divided into three groups: ACS group(n=335),stable angina(SA) group(n=120) and control group(n=120).ACS group was subdivided into unstable angina(UA) group of 134 patients,non-ST-segment elevation myocardial infarction(NSTMI) group of 80 patients and ST-segment elevation myocardial infarction(STMI) group of 121 patients.Serum OPG and its ligand(souble-RANKL,sRANKL) levels were measured by enzyme-linked immunosorbent assay(ELISA).The relationship between levels of OPG and sRANKL as well as the ratio of the two(OPG/sRANKL) and stabilization of coronary artery atherosclerosis was investigated.RESULTS: Serum OPG,sRANKL,and OPG/sRANKL ratios were different between ACS,SA and control groups(P0.01).Serum OPG,sRANKL and OPG/sRANKL ratios were different among the three subgroups of ACS group(P0.05).The difference between STMI group and UA group was significant(P0.05).The difference between UA group and NSTMI group and the difference between NSTMI group and STMI group were not significant.Gensini coronary points were positively correlated with both serum OPG levels(r=0.252,P0.01) and OPG/sRANKL(r=-0.284,P0.01),but negatively correlated with serum sRANKL levels(r=-0.235,P0.05).CONCLUSION: OPG and sRANKL levels and the ratio of the two(OPG/sRANKL) are associated with the stabilization of coronary artery atherosclerosis in patients with ACS.
出处 《心脏杂志》 CAS 2012年第6期704-707,共4页 Chinese Heart Journal
基金 军队医学科技创新项目资助(09MA094)
关键词 急性冠脉综合征 系统 骨保护素 acute coronary syndromes osteoprotegerin soluble receptor activator of nuclear factor coronary artery disease stabilization
  • 相关文献

参考文献9

  • 1谢钦菁,罗助荣.骨保护素作为预测心血管疾病发病率和死亡率的新标志物的研究进展[J].中华临床医师杂志(电子版),2011,5(10):2963-2966. 被引量:5
  • 2徐高阳,罗助荣.骨保护素系统与动脉粥样硬化的关系[J].中国动脉硬化杂志,2010,18(12):1004-1008. 被引量:6
  • 3Schoppet M,Sattler AM,Herzum M, et a1.Increased osteoprotegerin serum levels in men with coronary artery disease[].The Journal of Clinical Endocrinology.2003
  • 4OhmoriR,MomiyamaY,TaniguchiH.Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men[].Atherosclerosis.2006
  • 5Crisafulli A,Micari A,Altavilla D,et al.Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction[].Clinical Science Lond.2005
  • 6Omland T,Ueland T,Jansson AM, et al.Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes[].Journal of the American College of Cardiology.2008
  • 7Schoppet M,Schaefer JR,Hofbauer LC,et al.Low serum levels ofsoluble RANK ligand are associated with the presence of coronary ar-tery disease in men[].Circulation.2003
  • 8Sandberg WJ,Yndestad A,Qie E,et al.Enhanced T-cell expres-sion of RANK ligand in acute coronary syndrome:possible role inplaque destabilization[].Arteriosclerosis and Thrombosis.2006
  • 9Sandberg WJ,Yndestad A,Qie E,et al.Enhanced T-cell expres-sion of RANK ligand in acute coronary syndrome:possible role inplaque destabilization[].Arteriosclerosis and Thrombosis.2006

二级参考文献50

  • 1向光大,孙慧伶,赵林双,侯洁,乐岭,徐琳.1型糖尿病患者胰岛素治疗前后血浆护骨素的变化[J].中华医学杂志,2007,87(18):1234-1237. 被引量:32
  • 2Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel se-creted protein involved in the regulation of bone density [J]. Cell,1997,89(2):309-319.
  • 3Blair JM, Zheng Y, Dunstan CR. RANK ligand [J]. lnt J Biochem Cell Biol,2007,39(6):1 077-081.
  • 4Fan X, Roy E, Zhu L, et al. Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegefin expression in bone marrow stromal cells [J]. Endocrinology,2004,145(2):751-759.
  • 5Bergh JJ, Yihuan Xu, Mary C, et al. Osteoprotegerin expression and se2 cretion is regulated by calcium influx through the L-type voltage sensitive calcium channel [J]. Endocrinology,2004,145 (1):426-.436.
  • 6Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegrin/osteoclastogenesisinhibitory factor and is identi-cal to TRANCE/KANKL [J]. ProcNatlAcadSciUSA,1998,95(7):3 597-602.
  • 7Abedin M, Omland T, Ueland T, et al. Relation of osteoprptegerin tocoronary calcium and aortic plaque (from the Dallas Heart Study) [J]. Am J Cardiol,2007,99(4):513-518.
  • 8Sato K, Niessner A, Kopecky SL, et al. TRAIL-expressing T cells in-duce apoptosis of vascular smooth muscle ceils in the atherosclerotic plaque [J]. J Exp Med,2006,203(1):239-250.
  • 9Bennett BJ, Scatena M, Elizabeth A, et al. Osteorotegerin inactivation accelerates advanced athersclerotic lesion progression and calcification in older ApoE-/-mice [J]. Arterioscler Thromb Vasc Biol,2006,26(9):2 114-117.
  • 10Ovchinnikova O, Gylfe A, Bailey L, et al. Osteoprotegerin promotes fi-brous cap formation in atherosderotic lesions of ApoE-deficient mice-brief report [J]. Arterioscler Thromb Vase Biol,2009,29(10):1 478-480.

共引文献9

同被引文献24

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部